Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Common Equity: 2023-2025

Historic Common Equity for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to $196.4 million.

  • Zenas BioPharma's Common Equity fell 45.35% to $196.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.4 million, marking a year-over-year decrease of 45.35%. This contributed to the annual value of $312.5 million for FY2024, which is 238.43% up from last year.
  • Latest data reveals that Zenas BioPharma reported Common Equity of $196.4 million as of Q3 2025, which was down 18.03% from $239.6 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Common Equity ranged from a high of $359.4 million in Q3 2024 and a low of -$288.8 million during Q2 2024.
  • Moreover, its 3-year median value for Common Equity was $196.4 million (2025), whereas its average is $47.0 million.
  • Per our database at Business Quant, Zenas BioPharma's Common Equity surged by 277.73% in 2024 and then crashed by 45.35% in 2025.
  • Over the past 3 years, Zenas BioPharma's Common Equity (Quarterly) stood at -$225.7 million in 2023, then soared by 238.43% to $312.5 million in 2024, then tumbled by 45.35% to $196.4 million in 2025.
  • Its Common Equity stands at $196.4 million for Q3 2025, versus $239.6 million for Q2 2025 and $284.3 million for Q1 2025.